The rate of formation of thromboplastin was determined in several mammalian plasmas and sera.
I. INTRODUCTION
Recently we described (Fantl, Sawers, and Marr 1956 ) a haemorrhagic tendency of a male bleeder whose plasma contained an anticoagulant which inhibited specifically {3-prothromboplastin (PTC or Christmas factor) activity of normal human plasma. The anticoagulant was very likely an antibody produced by sensitization of the patient by blood transfusions. The lack of anticoagulant activity on animal plasma could be explained by the specificity of the antibody or could be due to a considerably higher concentration of {3-prothromboplastin in animal than human plasma. In the latter case the anticoagulant would neutralize a fraction of {3-prothromboplastin and the remaining excess would mask the anticoagulant activity. Therefore, activities and the species specificity of prothromboplastins of human and animal plasmas were determined.
II. METHODS .AND MATERIALS
Human blood was obtained by venipuncture from normal donors. Sheep blood was obtained from the jugular vein. Other animals were anaesthetized with ether. Rabbit blood was obtained from the exposed carotid artery through a siliconized cannula. Guinea pig and rat blood were taken from one of the ventricles. Dog blood was obtained from the femoral artery. As anticoagulants O·lM sodium oxalate or O·13M trisodium citrate were used. One volume of anticoagulant was mixed with nine volumes of blood. In the case of guinea pig and rat blood anticoagulant was already in the syringe. The thromboplastin generation test was carried out according to Biggs and Douglas (1953) , the modification of Bell and Alton being adopted (1954) , except that oxalated plasma treated with barium sulphate (Ba-plasma) was used instead of aluminium hydroxide-treated citrated plasma. Phospholipid was prepared from sheep brain according to Eagle (1935) . The partial thromboplastin test was carried out according to Langdell, Wagner, and Brinkhous (1953 The reaction mixtures contained 0·12 ml Ba-plasma, 0·06 ml homologous serum, 0·6 ml phospholipid suspension, 0·6 ml 0·025M CaCl" 1·02 ml 0·15M NaCl; substrate: homologous plasma. Technique of Biggs and Douglas (1953) .
a-Prothromboplastin deficient blood (a-haemophilia) and ,8-prothromboplastin deficient blood (PTC, Christmas disease) were taken from the respective patients and collected in a solution containing 0·104M trisodium citrate and 0'053M citric acid. The plasmas were stored at -15°C. SPCA test was carried out according to de Vries, Alexander, and Goldstein (1949) . Veronal buffer of ionic strength 0·15 was prepared according to Michaelis (1930) .
III. RESULTS
Thromboplastin formation was measured in reaction mixtures which consisted of homologous plasma and serum components. The results are given in Figure 1 where it can be seen that if homologous blood components with the exception of phospholipids are used maximum thromboplastin activity occurred after 5-6 min incubation time. The shortest clotting time was between 7 and 11 sec. A marked difference in stability of thromboplastin was apparent; whereas the thromboplastins of rabbit and that of man were stable for some minutes, guinea pig and rat thromboplastin activity diminished after 1 min.
It should be pointed out that whereas the blood specimens from man, rabbit, and sheep were obtained with the least trauma, the guinea pig and rat blood were certainly contaminated with tissue thromboplastin. Spaet and Garner (1955) have indicated a certain similarity between the thromboplastin inactivator present in plasma and antithrombin. Since it has been found that phenols inactivate antithrombin (Fantl 1954) , the influence of catechol on blood thromboplastin was determined. The results are given in Figure 2 . . It is apparent from Figure 2 that although there is a lag in the formation of thromboplastin in the presence of catechol, this substance has some stabilizing effect on thromboplastin which is far more pronounced with human material than with that of the rat. Maximum thromboplastin formation and stability of human thromboplastin was determined in a number of instances and the results are given in Table 1 .
The results in Table 1 indicate that veronal buffers at pH 6·8-7·5 did not influence the result although a lag period in the formation of thromboplastin is apparent. This is very pronounced in the presence of catechol, but the stabilizing effect of catechol is quite noticeable. In the following experiments the ability to form thromboplastin was tested in reaction mixtures containing human Ba-plasma and human or animal sera. Results are given in Figure 3 , where it can be seen that thromboplastins formed from human Ba-plasma, and heterologous serum were less active than thromboplastins formed from homologous human blood components. In other experiments different brain phospholipids and also human platelets were used as a source of phospholipids; substantially similar results to those in Figure 3 were obtained. From the activities of a series of dilutions of human thromboplastin it was estimated that the percentage relative activity of thromboplastins formed from human Ba-plasma in the presence of serum was: human 100, rabbit and sheep 30-45, guinea pig 20-30, rat 5-15. These values are considerably lower than those found in homologous reaction mixtures (Fig. 1) . The low potency of the thromboplastins formed in the presence of heterologous sera could be due to species specificity of the thromboplastins or to a reduced activity of anyone of the serum factors, or of the Ba-plasma towards the heterologous components required for thromboplastin formation.
In order to see whether the thromboplastins showed species specificity, the various mammalian plasma thromboplastins were produced by incubating serum and homologous Ba-plasma; the reaction mixtures were tested on homologous as well as heterologous plasma. Results are given in Table 2 . From this table it is seen that although there were differences in thromboplastin activity among the various thromboplastins, the reaction mixtures showed the same clotting times with homologous as with heterologous plasma as substrate. Apparently there was no species specificity of blood thromboplastin.
Independent determinations of each factor required for the formation of blood thromboplastin were carried out in order to find which factor showed species specificity. The a-prothromboplastin activity was estimated from the results of two independent techniques in which the correcting influence of normal animal or human plasma added to the plasma of patients with a complete deficiency of a-prothromboplastin was measured. The results are given in Table 3 , and indicate that the plasmas of man, rabbit, guinea pig, and rat were not significantly different in their a-prothromboplastin activity. Dog plasma showed higher activity.
,8-Prothromboplastin activity of the various plasma and sera was tested for ability to restore the deficiency of plasma or sera of patients with a complete lack of ,8-prothromboplastin. These results are given in Table 4 . They show that the plasma or sera of normal man, rabbit, guinea pig, and rat are not significantly different in their ,B-prothromboplastin activity. Dog plasma had a higher activity. It will be noted that the guinea pig or rat serum was considerably more active in the tests given in Table 4 than in the experiments in Figure 3 .
There was no inhibition of thromboplastin formation in mixtures of guinea pig . or rat i!Jerum with human serum and human Ba-plasma. Therefore the low yield of thromboplastin from human Ba-plasma and animal sera cannot be due to inhibitors of thromboplastin formation in the animal sera.
It would seem therefore that neither a-nor ,B-prothromboplastin shows a decreased affinity to the other factors in reaction mixtures containing heterologous clotting components. It appears that the species specificity noted in Figure 3 was due to a different factor present in serum which may belong to the proconvertinconvertin complex.
As patients with such deficiencies (SPCA, proconvertin, factor 7, Stewart factor) were not available, the appropriate tests could not be carried out. Instead the animal sera were tested for serum accelerator factors in combination with brain thromboplastin with the technique of de Vries et al. (1949) . The results are et al. (1949) . t 0·0855 ml human Ba-plasma, 0·0045 ml human oxalated plasma, 0·1 ml 6% human brain suspension in 0'15M NaCl. t 0·08775 ml rabbit Ba-plasma, 0·00225 ml rabbit oxalated plasma, 0·1 ml 3% rabbit brain suspension in 0·15M NaCl. § 0·08775 ml guinea pig Ba-plasma, 0·00225 ml guinea pig oxalated plasma, 0·1 ml 3% guinea pig brain suspension in 0'15M NaCl. listed in Table 5 , and indicate that the shortest clotting times were observed in reaction mixtures which contained homologous components only. These results in conjunction with the previous observations indicate that it is a serum factor of the proconvertin-convertin complex which shows species specificity.
IV. DISCUSSION
A comparison of the rate of formation and yield of thromboplastin in homologous and heterologous clotting systems indicated that only some of the clotting factors are species specific. This seems remarkable because most of the clotting factors are proteins and one would expect that all or none of them show greater affinity to homologous than to heterologous components of the clotting system. Several mammalian plasmas with the exception of that of the dog had a similar activity to normal human plasma in correcting the clotting defect of patients with a-or {3-haemophilia.
Other workers found a-prothromboplastin activity of plasma as follows: man 100, rabbit 100, rat 100, dog 200, beef-cattle 400 (Richards and Spaet 1956 ); beef-cattle 1300 (Biggs, Eveling, and Richards 1955) , rabbit 500 (Egli and Kesseler 1955) . The {3-component has apparently not been investigated by other workers. Since it is unlikely that thromboplastin precursors show higher affinity to foreign proteins than to their own plasma components it seems that the observed a-or {3-prothromboplastin activity irrespective of source is only dependent upon concentration. a-and {3-prothromboplastin are therefore not species specific.
This suggests that the blood thromboplastin precursors contain active centres for the coagulation process which are distinct from those essential for antigenicity, since the inhibitor of human {3-prothromboplastin activity which was present in the blood of a male bleeder (Fantl et al. 1956 ) did not inactivate the {3-prothromboplastins of the plasma of several animals.
In addition to the two thromboplastin precursors mentioned other factors are required for optimum thromboplastin formation. One of them, prothrombin accelerator (proaccelerin, labile factor, factor 5) shows usually higher activity in animal than in human plasma and it has been noticed elsewhere (Fantl and Ward, unpublished data) that this clotting factor is not species specific. Other components required for optimum thromboplastin formation are present in the proconvertinconvertin complex. This has not been resolved into individual constituents, and it is therefore not possible to indicate which one of them is involved in thromboplastin formation. However the combination of heterologous sera with human Ba-plasma resulted in thromboplastins of lower potency, than expected from the a-and {3-prothromboplastin activities. This indicated not only that additional serum factors are required for efficient thromboplastin formation but also that one or more of the unidentified factors show pronounced species specificity.
Thromboplastins of organ extracts usually give shorter clotting times with homologous than with heterologous substrates. This was not apparent in experiments where blood thromboplastin containing reaction mixtures were tested on human and heterologous plasma. The reason for this apparent lack of species specificity is probably due to the presence of serum. This is comparable to the observation made by Burstein (1950) and by Mann and Hurn (1952) who found that incubation of brain extracts with homologous sera abolished species specificity. 
